RXRX: Recursion Pharmaceuticals, Inc. Stock

by  •  • Comments Off on RXRX: Recursion Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,767.09
Enterprise Value ($M) 1,340.53
Book Value ($M) 524.56
Book Value / Share 1.88
Price / Book 3.37
NCAV ($M) 272.23
NCAV / Share 0.97
Price / NCAV 6.49

Profitability (mra)
Return on Invested Capital (ROIC) -0.61
Return on Assets (ROA) -0.58
Return on Equity (ROE) -0.82

Liquidity (mrq)
Quick Ratio 4.35
Current Ratio 4.35

Balance Sheet (mrq) ($M)
Current Assets 474.17
Assets 726.50
Liabilities 201.94
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-12 13G/A Fmr Llc 3.04 -23.25
11-12 13G/A Vanguard Group Inc 8.82 0.00
11-08 13G/A BlackRock, Inc. 7.50 0.00
11-04 13G/A Kinnevik AB (publ) 4.30 14.42
10-18 13G/A State Street Corp 4.70 5.91
07-08 13G Ra Capital Management, L.p. 5.90
02-12 13G/A ARK Investment Management LLC 11.08 11.73
01-26 13G/A Baillie Gifford & Co 11.61 -2.58

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION R
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPOR
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-15 2,433,839 12,161,430 20.01
2025-01-14 3,803,102 16,857,889 22.56
2025-01-13 3,017,354 11,439,502 26.38
2025-01-10 3,355,379 12,386,365 27.09

(click for more detail)

Similar Companies
RPRX – Royalty Pharma plc RPTX – Repare Therapeutics Inc.
RVMD – Revolution Medicines, Inc. SANA – Sana Biotechnology, Inc.
SCPH – scPharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io